Bladder Cancer Determination Via Two Urinary Metabolites: A Biomarker Pattern Approach

Abstract

The purpose of this study was to use metabonomic profiling to identify a potential specific biomarker pattern in urine as a noninvasive bladder cancer (BC) detection strategy. A liquid chromatography-mass spectrometry based method, which utilized both reversed phase liquid chromatography and hydrophilic interaction chromatography separations, was performed, followed by multivariate data analysis to discriminate the global urine profiles of 27 BC patients and 32 healthy controls. Data from both columns were combined, and this combination proved to be effective and reliable for partial least squares-discriminant analysis. Following a critical selection criterion, several metabolites showing significant differences in expression levels were detected. Receiver operating characteristic analysis was used for the evaluation of potential biomarkers. Carnitine C9:1 and component I, were combined as a biomarker pattern, with a sensitivity and specificity up to 92.6% and 96.9%, respectively, for all patients and 90.5% and 96.9%, respectively for lowgrade BC patients. Metabolic pathways of component I and carnitine C9:1 are discussed. These results indicate that metabonomics is a practicable tool for BC diagnosis given its high efficacy and economization. The combined biomarker pattern showed better performance than single metabolite in discriminating bladder cancer

Developing Urinary Metabolomic Signatures as Early Bladder Cancer Diagnostic Markers

“…For the choice of biofluid samples, urine seems to be the ideal reservoir from which BCa diagnostic marker can be derived, as it is in direct contact with the cancer lesion on the bladder transitional epithelium. Based on this rationale, urinary metabolomics studies for BCa diagnosis has been carried out previously with various analytical platforms, including GC-MS, NMR and LC-MS (Huang et al, 2011, Issaq et al, 2008, Jobu et al, 2012, Pasikanti et al, 2010, Srivastava et al, 2010.…”

Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers

“…Metabolomics, a growing field in systems biology (9 -11), has been shown to be a powerful approach to quantitatively measure global changes in the metabolic profiles of individuals in response to disease or treatment via noninvasive analyses of biofluids (12)(13)(14)(15)(16). Hence, metabolomics represents an excellent developing prospect for the discovery of diagnostic and therapeutic biomarkers.…”

Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer

“…Various studies using mass spectrometric (MS) methods reported promising results for bladder cancer (BCa) detection and separation of invasive BCa from non-invasive BCa (Issaq et al, 2008;Huang et al, 2011;Pasikanti et al, 2013;Chan et al, 2015;Zhou et al, 2016). However, cohort sizes were small in most studies and the effects of renal cancer and bladder inflammation were the major problem in BCa detection (Van et al, 2011).…”